PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june)

www.pharmarc.com

ASCO 2011 Twitter Analytics June 3 – 7, 2011, Chicago, Illinois

Prepared by:

PharmARC Analytic Solutions

Rohit Kumar

[email protected]

+91 97314 58005

© PharmARC Analytic Solutions Pvt. Ltd., 2009 Slide 2

Contents

Top Links and Abstracts Shared at ASCO (3rd – 7th June)

Tweets on Molecules at ASCO (29th May – 7th June)


Top Links and Abstracts Shared (June 3rd – 7th)


Top Links Shared (1/4)

These are the top stories (URLs/links) shared most in twitter, for the Twitter hashtag ASCO11 (shared as tiny URLs)• The ones shared below include only the ones that were tweeted/re-tweeted the most from 3rd June through 7th June

Title URL Salient Points

Cancer’s New Era Of Promise And Chaos

http://blogs.forbes.com/matthewherper/2011/06/05/cancers-new-era-of-promise-and-chaos/

George Sledge, the outgoing president of the ASCO, talks about the changing paradigm in oncology w.r.t. new technology (genomic chaos, ‘stupid’ vs. ‘smart’ cancers, biomarkers validating the genomics, enormous data generation, health information technology)

Every oncologist will need to be a clinical cancer biologist 216 LinkedIn shares; tweeted >50 times

NCI at ASCO 2011: Partnering for Progress

http://www.cancer.gov/researchandfunding/meetings/2011asco?cid=Tasco_ocs

Mentions the ASCO sessions and activities at National Cancer Institute booth Tweeted >45 times

Should Twitter be Restricted at Scientific Meetings?

http://33charts.com/2011/06/twitter-restricted-meetings.html

Apparently some meetings such as the Biology of Genomes Conference at Cold Spring Harbor Laboratory, presenters have to grant permission to allow the use of Twitter (this apparently will not be the case at ASCO)

Tweeted >25 times

Ovarian Cancer Screening Does Not Appear to Reduce Risk of Ovarian Cancer Death

http://digitalnewsrelease.com/index.php?q=JAMA_3792

JAMA publication: “We conclude that annual screening for ovarian cancer as performed in the PLCO trial with simultaneous CA-125 and transvaginal ultrasound does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms,” the author (Christine D. Berg, M.D.) writes

Tweeted >20 times

Random attacks cause concern in Chicago

http://www.chicagotribune.com/news/local/ct-met-mob-attacks-20110606,0,7509040.story?track=rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+chicagotribune%2Fnews%2Flocal+(Chicago+Tribune+news+-+Local+news)

"I think it reflects badly on Chicago," said Dr. Jack Singer, 68, a Seattle oncologist who was one of two victims in town for a convention of cancer specialists at McCormick Place. "I've been coming to the convention every year, and this is the first time I've felt threatened downtown.“

Tweeted ~20 times

The University of Texas The M.D. Anderson Cancer Center

http://physicianrelations.org/asco2011/

Info about the M.D. Anderson Cancer Center and ASCO Tweeted ~20 times




Scientific Meetings through the Lens of Twitter

http://www.cancer.gov/ncicancerbulletin/053111/page7

One of the most useful things about Twitter at meetings is the real-time feedback from colleagues who come at the talks from different angles – Dr. David Kroll of North Carolina Central University

Concerns about the accuracy of tweets may contribute to the reluctance of some presenters to have their work tweeted during meetings, particularly unpublished findings that have not been through peer review

Tweeted ~20 times

Novartis Oncology global site

http://www.novartisoncology.com/media/?usertrack.filter_applied=true&NovaId=4029462017804965268

Novartis oncology media page, providing links including news from ASCO Tweeted ~15 times

SaveMyFertility.org Home page

http://savemyfertility.org/

Authoritative resource for adult cancer patients and the parents of children with cancer who want to learn more about preserving their fertility before and during cancer treatment, and protecting their hormonal health after treatment

Tweeted ~15 times

Clinical Trials Day at ASCO

http://chicago2011.asco.org/AbouttheMeeting/WhatsNewin2011/ClinicalTrialsDay.aspx

Monday, June 6, the Clinical Trials Day at the Annual Meeting Features sessions that focus on a variety of themes relevant to the progress of clinical trials Tweeted ~15 times

Amgen medical info page

http://m.amgenmedinfo.com/home/support

Links for iPhone/iPad, Blackberry and Android (coming soon) for Amgen medical information download

Tweeted ~15 times

Direct-to-Consumer Genetic Testing:Personalized Medicine in Evolution

http://www.genomicslawreport.com/wp-content/uploads/2011/06/ASCO-DTC-Abstract.pdf

DTC genetic testing has the potential to launch personalized medicine to a height never before anticipated if technologic, social, and ethical issues are effectively addressed

Tweeted ~15 times

ASCO 2011 Annual Meeting schedule

http://www.physicianrelations.org/default/pdfs/asco2011/docmpresentations.pdf

Details of the poster sessions (schedule) Tweeted >10 times




ASCO Experiment: One-Stop Commenting for Cancer Research

http://blog.wcgworld.com/2011/06/asco-experiment-one-stop-commenting-for-cancer-research

Proposes ASCO opening up its abstracts to commenting Shares a spreadsheet collating comments from social media on some ASCO abstracts Tweeted >10 times

New Glioblastoma Cancer Vaccine Shows Promise in Phase 2 Trial

http://www.ucsf.edu/news/2011/06/9970/new-glioblastoma-cancer-vaccine-shows-promise-phase-2-trial

"This study confirms our theory that a vaccine is capable of causing a favorable immune response in patients with brain tumors,” said Jeffrey Bruce, MD, Edgar M. Housepian Professor of Neurological Surgery Research at New York-Presbyterian Hospital/Columbia University Medical Center

Tweeted >10 times

Personalized Therapy Benefits Late-Stage Cancer Patients in Clinical Trial

http://www2.mdanderson.org/cancerwise/2011/06/personalized-cancer-therapy-benefits-late-stage-cancer-patients-in-clinical-trial.html#more

"This study affirms what we in the cancer community have been talking about for a decade -- matching drugs to patients," says Razelle Kurzrock, M.D., chair of the Department of Investigational Therapeutics and director of MD Anderson's Phase I clinical trials program

Tweeted >10 times

“The Cancer That Gives Cancer a Bad Name”: Important News on the Treatment of Advanced Melanoma

http://www.cancer.org/AboutUs/DrLensBlog/post/2011/06/05/Important-News-on-the-Treatment-of-Advanced-Melanoma-The-Cancer-That-Gives-Cancer-a-Bad-Name.aspx#continue

Dr. Len’s cancer blog “I don't keep a record of these sorts of things, but I suspect the speed of "start to finish" to

prove significant improvement in responses and survival is right up there with the fastest clinical trials on record. The reason for this "record" is pretty clear when you read the report and look at the data: almost every patient who was treated with vemurafenib responded to the drug, and most of them responded very quickly.”

Tweeted ~10 times

Primary Care Doctors and Medical Oncologists Have Different Concerns About Providing Survivorship Care

http://www.cancer.net/patient/Cancer+News+and+Meetings/ASCO+Annual+Meetings/Research+Summaries/Survivorship/Primary+Care+Doctors+and+Medical+Oncologists+Have+Different+Concerns+About+Providing+Survivorship+Care

Medical oncologists were more likely to be concerned that patients might get duplicate care and about which doctor should provide general preventive care

Primary care doctors were more concerned about having appropriate training to provide sufficient follow-up care. They were also more likely than oncologists to recommend additional tests or treatments out of concerns of malpractice

According to lead author Katherine Virgo, PhD, MBA, Managing Director of Health Services Research at the American Cancer Society in Atlanta, it’s important for patients to talk with both their oncologist and primary care doctor and make sure that information about their treatment and follow-up care recommendations is being shared

Tweeted ~10 times




Melanoma: Ready for Takeoff

http://curetoday.com/index.cfm/fuseaction/article.showArticleByTumorType/id/826/tumorCategory/Skin/article_id/1693

“It’s possible that you can combine targeted agents along the same circuit, like a BRAF drug and an MEK inhibitor,” says Hwu, department chairman of the melanoma medical oncology department at M.D. Anderson Cancer Center in Houston. “Or you can combine two targeted agents on separate circuits.”

As one example, GlaxoSmithKline has launched a series of studies looking at an MEK inhibitor (GSK1120212) and a BRAF inhibitor (GSK2118436), both separately and in combination

Tweeted ~10 times

The University of Texas MD Anderson Cancer Center Education Page

http://www.mdanderson.org/education-and-research/education-and-training/schools-and-programs/graduate-medical-education/residency-and-fellowship-programs/index.html

Lists the Residency and Fellowship Programs Tweeted ~10 times

ASCO '11: Roche, Bristol Melanoma Drugs Shine

http://www.thestreet.com/story/11142848/1/asco-11-roche-bristol-melanoma-drugs-shine.html

Bristol's Yervoy was approved earlier this year and Roche's vemurafenib is still under regulatory review, but both drugs could generate $1 billion or more in sales, analysts say

Tweeted ~10 times

The Genomic Era: We Have Reached A New Tipping Point In Cancer Research And Treatment

http://www.cancer.org/AboutUs/DrLensBlog/post/2011/06/06/The-Genomic-Era-We-Have-Reached-A-New-Tipping-Point-In-Cancer-Research-And-Treatment.aspx#continue

There was one lecture where the researcher showed a large box that looked to be the size of a refrigerator which can analyze the entire genome of a person or a cancer over a matter of days, followed by the prediction (that many share) that these types of tests--which were the stuff of science fiction just a few short years ago--will be routine at a reasonable cost in a very short period of time (in fact, some well-known cancer centers are already employing this technology as part of their routine evaluation of a patient's cancer)

Tweeted ~10 times

ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S.

http://www.xconomy.com/national/2011/06/07/asco-wrap-up-the-skinny-on-cancer-news-from-all-corners-of-the-u-s/

Summary of what the companies presented at ASCO (Ariad Pharmaceuticals, Infinity Pharmaceuticals, Synta Pharmaceuticals, Alnylam Pharmaceuticals, Constellation Pharmaceuticals, Genentech/Plexxikon, Exelixis, ACT Biotech, Onyx Pharmaceuticals, Genomic Health, Dendreon, Seattle Genetics, Pfizer, Merck, VentiRx Pharmaceuticals, Ligand Pharmaceuticals)

Tweeted ~10 times


Top Abstracts Shared


Effect of screening on ovarian cancer mortality in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer randomized screening trial

http://abstract.asco.org/AbstView_102_84255.html

Screening simultaneously with CA-125 and TVU did not reduce ovarian cancer mortality in women from the general population, and there was evidence of harm from diagnostic evaluation following a false positive screening test.

Tweeted ~20 times

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma


IPI (10mg/kg) + DTIC significantly improved OS in 1st line metastatic melanoma vs DTIC alone; durable survival and objective responses were noted in some pts after follow-up for up to 4yrs. Type of AEs was consistent with prior IPI studies; however, frequencies of some AEs differed with a higher transaminitis and lower diarrhea/colitis/ GI perforation rates than expected. No drug-related deaths were noted in IPI arm. OS benefit of IPI is confirmed in treatment-naive metastatic melanoma

Tweeted ~15 times

OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)


Results show a statistically significant and clinically relevant benefit when bevacizumab is added to chemotherapy in patients with recurrent, platinum sensitive EOC, PPC, and FTC. This is the first phase III trial of an antiangiogenic to demonstrate a clinical benefit to these patients

Tweeted ~15 times

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma


Vemurafenib is associated with significantly improved OS and PFS compared to DTIC in pts with previously untreated, V600EBRAF-mutated metastatic melanoma

Tweeted ~15 times

NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer


The majority of women with node positive breast cancer are now managed by BCS followed by WBI and adjuvant systemic therapy. Results from MA.20 demonstrate that additional RNI reduces the risk of locoregional and distant recurrence, and improves DFS with a trend in improved OS

Tweeted >10 times

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial


BuMel was demonstrated to be superior to CEM and hence is recommended as standard treatment

Tweeted >10 times


Tweets on Molecules (29th May – 7th June)


More than 15 Peak Tweets

bevacizumab: the most buzzed drug at ASCO 2011vemurafenib-ipilimumab: a new era for the melanoma treatment – BMS & Roche combination therapy


0

2

4

6

8

10

12

29-May-11 30-May-11 31-May-11 1-Jun-11 2-Jun-11 3-Jun-11 4-Jun-11 5-Jun-11 6-Jun-11 7-Jun-11

# of Tweets

Abraxane Alimta Alpharadin, Zytiga Aromasin, Axitinib

Axitinib Bevacizumab, Abraxane Dasatinib, Glivec Ipilimumab, Bevacizumab

Revlimid Ridaforolimus Ruxolitinib Zaltrap

Zytiga

Less than 15 Peak Tweets


vemurafenib (PLX 4032)

Ipilimumab & vemurafenib - Melanoma takes center stage– BRIM-3 editorial: Vemurafenib’s availability a defining moment; will have important effect on survival, QOL

– Lynn Schuchter, Penn: on trial results (vemurafenib, ipilimumab+dacarbazine) - an unprecedented time for celebration for patients

– Melanoma smart pill #vemurafenib starts working in 72 hours, Prof Lynn Schuchter tells

– Maybe I'm in a minority, but ipilimumab data are a tad disappointing - 2 months OS over DTIC. Vemurafenib data more impressive

– BRAF vemurafenib data impressive w/ incr ORR PFS&OS:a1st! duration may be short -resistance is inevitable & opp for new

drugs/combos

– personalized med finally becoming a reality,eg $ROG vemurafenib for melanoma; $ECYT EC145 for

– Third post-plenary thought re: #melanom--how long until Vemurafenib no longer monotherapy? Lots of combos in the works

#asco11play resistant ovarian cancer

– Melanoma_doctor: Vemurafenib ("V-Fib") shows 73% reduction in risk of death. Pretty damn significant

– Vemurafenib article #NEJM w/ improved OS + PFS for #melanoma pts, FDA approval inevitable

– Is #Melanoma Rhetoric Outpacing Reality? Vemurafenib & Yervoy Have Limitations Despite Positive Trials. Why?

http://bit.ly/9qLkWA #ASCO11

• http://inthought.ning.com: Has the historical dearth of viable pharmacotherapies for malignant melanoma led to an overreaction

to the positive phase III Yervoy and vemurafenib data presented at the plenary session?

Cost concerns

– If the vemurafenib-ipilimumab combo data come in positive, where will the costs go? Through the roof :( #asco11)


Yervoy (ipilimumab)

Ipilimumab & vemurafenib - Melanoma takes center stage– Tweets discuss BMS & Roche combination therapy (vemurafenib-ipilimumab) being in the limelight

– Maybe I'm in a minority, but ipilimumab data are a tad disappointing - 2 months OS over DTIC. Vemurafenib data more

impressive #asco11

– Is #Melanoma Rhetoric Outpacing Reality? Vemurafenib & Yervoy Have Limitations Despite Positive Trials. Why?

http://bit.ly/9qLkWA #ASCO11

• http://inthought.ning.com: Has the historical dearth of viable pharmacotherapies for malignant melanoma led to an

overreaction to the positive phase III Yervoy and vemurafenib data presented at the plenary session?

Cost concerns– If the vemurafenib-ipilimumab combo data come in positive, where will the costs go? Through the roof :( #asco11

– @teamoncology to put it in context, if you need ipilimumab, your 20% co-pay will be $24K. Yikes. #asco11


Avastin (bevacizumab)

Bevacizumab in ovarian cancer (OCEANS trial) was most tweeted– #ASCO11 practical considerations. Bevacizumab in ovarian cancer manage HTN aggressively. Waiting for oceans/icon 7

later today

– #ASCO11 Avastin shows trend towards improved OS in ICON7 ovarian cancer trial, greater effect in high risk patients.

Good for approval? Nope

– #asco11 Avastin in Ovarian Cancer ~ no big surprise with +ve data! Wonder if FDA will drag feet to approve or will move

quickly? LBA5006/7

Cost concerns– 45% of Avastin use in United Heath Group centers is used outside NCCN guidelines #ASCO11 HUGE cost


Tarceva (erlotinib)

Erlotinib is superior to chemotherapy in EGFR mutated NSCLC patients and expects FDA filing– Longtime member of @cancerGRACE community wants me to hug makers of Tarceva at #ASCO11 for him, as his wife is

doing very well on it

– INNOVATIONS subgrp analysis of EGFR Mut+ interesting -small numbers. Q: Beva interfere with erlotinib

delivery/efficacy? #ASCO11 #BOPA

– Erlotinib/bev vs. chemo/bev as 1st line Rx for adv nonsquam NSCLC, no select'n for EGFR mutn: chemo/bev clearly

better, dets later #ASCO11

– EURTAC study: RR diff 58% vs. 14%, along w/huge PFS diff 9.7 vs 3.2 mo favoring erlotinib in EGFR mut NSCLC pts.

Expect FDA filing. #ASCO11


Revlimid (lenalidomide)

Lenalidomide for the treatment of Multiple Myeloma and Prostate Cancer proves impressive– Ravandi now reviewing Revlimid in MDS (Alan list abstract). Also says new agents in dev for AML are promising and worth

pursuing #ASCO11

– #ASCO11 #myeloma Lenalidomide is a fundamental drug in the treatment of Multiple Myeloma

– Avastn/Revlimid/Tax combo data in PCa was early, but impressive. Toxic, but not as bad as I would have guessed

1D/4574 #ASCO11


Glivec (imatinib)

3 years Glivec improves RFS / OS in patients with GIST– #ASCO11: 3 yrs of imatinib for GIST likely "will be standard," says Heikki Joensuu, M.D., University of Helsinki.

(SSGXVIII/AIO trial)

– #ASCO11: Imatinib results in GIST (SSGXVIII/AIO trial): "This is the kind of data that will change guidelines." Mark Kris,

Sloan-Kettering


Alimta (pemetrexed)

Maintenance therapy with Alimta for NSCLC was most tweeted– Likely to be biggest practice changing abstract for NSCLC at #ASCO11 maintenance pemetrexed vs BSC

– Overall, amrubicin v topotecan trial reminds me of topo v CAV in SCLC, or pemetrexed v docetaxel in NSCLC. I'd

welcome amru option


Zytiga (abiraterone)

Cost concerns– Drake: With cost structure of abiraterone, docs will still use ketoconozole #ASCO11

– @MaverickNY I disagree. Zytiga more expensive for Medicare *patients* than Provenge. #ASCO11

– William Oh - pca mkt getting crowded (cabazitaxel, abiraterone, sipu, etc) w more in late stage trials (alpharadin, Prostvac,

etc) #asco11


Aromasin (exemestane)

Breast cancer– Exemestane’s data for breast cancer prevention is impressive

– @MaverickNY Exemestane is a possible alternative for Tamoxifen. But long-term data & safety needed. Need FDA

approval before use. #ASCO11


Other molecules

Ridaforolimus

– Was discussed mostly as a maintenance therapy

axitinib (AG013736)

– Outperforms sorafenib in Renal Cell Carcinoma

Sprycel (dasatinib)

– Shows superior major molecular response over imatinib

alpharadin (radium-223)

– William Oh - pca mkt getting crowded (cabazitaxel, abiraterone, sipu, etc) w more in late stage trials (alpharadin,

Prostvac, etc) #asco11

Abraxane (paclitaxel )

– CELG Sticking With Abraxane (despite bad data at #ASCO11)

Zaltrap (aflibercept)

– Significantly Improved Survival in Previously Treated Metastatic #ColonCancer

Ruxolitinib (INCB-018424)

– Decreases the spleen size in myelofibrosis

Corporate Headquarters

PharmARC Analytic Solutions Pvt. Ltd., Mercury 2B Block, 6th Floor, Prestige Technology Park, Sarjapur Marathahalli Outer Ring, Road, Bangalore – 560 103, India.Phone: +91 (80) 4123 8900 (Main); Fax: +91 (80) 4123 8999

© PharmARC Analytic Solutions Pvt. Ltd., 2009

For further information on the analytics, please contact:

Rohit KumarProduct Director

[email protected]

+91 97314 58005

Documents

PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june)